CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
d-Methadone +2 moredrug
Likely dose
d-Methadone 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00588640
NCT00588640Phase 2Completed
CompareCT.gov

A Phase I/II Study of D-Methadone in Patients With Chronic Pain

Memorial Sloan Kettering Cancer Center·interventional·Posted Jan 8, 2008·Updated Aug 10, 2016

In Brief

A Phase 2 clinical trial evaluating d-Methadone, D-methadone, and 1 other intervention for Pain and 11 related conditions. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the safest dose of d-methadone that can be given, without causing severe side effects in most patients with chronic pain. Patients are being asked to participate in the Phase I portion of this study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain, Bladder Cancer, Breast Cancer, CNS Cancer, Colon Cancer, Esophageal Cancer, Pancreatic Cancer, Prostate Cancer, Uterine Cancer, Head and Neck Cancer, Eye Cancer, Otorhinolaryngologic Neoplasms
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 8, 2008
Enrollment StartOct 1, 2004
Primary CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 18.5 years ago

Interventions

d-Methadonedrug

8 subjects to receive 40 mg d-Methadone twice a day

D-methadonedrug

After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.

placebodrug

After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.